caa a22 4500 445315210 CHVBK 20180317142644.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1007/s10552-011-9847-z doi (NATIONALLICENCE)springer-10.1007/s10552-011-9847-z Aspirin and NSAID use and lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO) [Elektronische Daten] [Valerie McCormack, Rayjean Hung, Darren Brenner, Heike Bickeböller, Albert Rosenberger, Joshua Muscat, Philip Lazarus, Anne Tjønneland, Søren Friis, David Christiani, Eun-mi Chun, Loic Le Marchand, Gad Rennert, Hedy Rennert, Angeline Andrew, Irene Orlow, Bernard Park, Paolo Boffetta, Eric Duell] Purpose: To investigate the hypothesis that non-steroidal anti-inflammatory drugs (NSAIDs) lower lung cancer risk. Methods: We analysed pooled individual-level data from seven case-control and one cohort study in the International Lung Cancer Consortium (ILCCO). Relative risks for lung cancer associated with self-reported history of aspirin and other NSAID use were estimated within individual studies using logistic regression or proportional hazards models, adjusted for packyears of smoking, age, calendar period, ethnicity and education and were combined using random effects meta-analysis. Results: A total of 4,309 lung cancer cases (mean age at diagnosis 65years, 45% adenocarcinoma and 22% squamous-cell carcinoma) and 58,301 non-cases/controls were included. Amongst controls, 34% had used NSAIDs in the past (81% of them used aspirin). After adjustment for negative confounding by smoking, ever-NSAID use (affirmative answer to the study-specific question on NSAID use) was associated with a 26% reduction (95% confidence interval 8 to 41%) in lung cancer risk in men, but not in women (3% increase (−11% to 30%)). In men, the association was stronger in current and former smokers, and for squamous-cell carcinoma than for adenocarcinomas, but there was no trend with duration of use. No differences were found in the effects on lung cancer risk of aspirin and non-aspirin NSAIDs. Conclusions: Evidence from ILCCO suggests that NSAID use in men confers a modest protection for lung cancer, especially amongst ever-smokers. Additional investigation is needed regarding the possible effects of age, duration, dose and type of NSAID and whether effect modification by smoking status or sex exists. Springer Science+Business Media B.V., 2011 NSAIDs nationallicence Aspirin nationallicence Lung cancer nationallicence McCormack Valerie Section of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69008, Lyon, France aut Hung Rayjean Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, Canada aut Brenner Darren Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, Canada aut Bickeböller Heike Department of Genetic Epidemiology Medical School, Georg-August-University of Göttingen, Göttingen, Germany aut Rosenberger Albert Department of Genetic Epidemiology Medical School, Georg-August-University of Göttingen, Göttingen, Germany aut Muscat Joshua Pennsylvania State Cancer Institute, Pennsylvania State College of Medicine, Hersey, PA, USA aut Lazarus Philip Pennsylvania State Cancer Institute, Pennsylvania State College of Medicine, Hersey, PA, USA aut Tjønneland Anne Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark aut Friis Søren Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark aut Christiani David Harvard School of Public Health, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA aut Chun Eun-mi Harvard School of Public Health, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA aut Le Marchand Loic Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, USA aut Rennert Gad Department of Community Medicine and Epidemiology, Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Israel Institute of Technology and Clalit Health Services National Cancer Control Center, Haifa, Israel aut Rennert Hedy Department of Community Medicine and Epidemiology, Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Israel Institute of Technology and Clalit Health Services National Cancer Control Center, Haifa, Israel aut Andrew Angeline Norris Cotton Cancer Center, Department of Community & Family Medicine, Dartmouth Medical School, Lebanon, NH, USA aut Orlow Irene Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut Park Bernard Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut Boffetta Paolo Tisch Cancer Institute and Institute for Translational Epidemiology, Mount Sinai School of Medicine, New York, NY, USA aut Duell Eric Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain aut Cancer Causes & Control Springer Netherlands 22/12(2011-12-01), 1709-1720 0957-5243 22:12<1709 2011 22 10552 https://doi.org/10.1007/s10552-011-9847-z text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10552-011-9847-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- McCormack Valerie Section of Environment and Radiation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69008, Lyon, France aut NATIONALLICENCE 700 1- Hung Rayjean Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, Canada aut NATIONALLICENCE 700 1- Brenner Darren Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, Canada aut NATIONALLICENCE 700 1- Bickeböller Heike Department of Genetic Epidemiology Medical School, Georg-August-University of Göttingen, Göttingen, Germany aut NATIONALLICENCE 700 1- Rosenberger Albert Department of Genetic Epidemiology Medical School, Georg-August-University of Göttingen, Göttingen, Germany aut NATIONALLICENCE 700 1- Muscat Joshua Pennsylvania State Cancer Institute, Pennsylvania State College of Medicine, Hersey, PA, USA aut NATIONALLICENCE 700 1- Lazarus Philip Pennsylvania State Cancer Institute, Pennsylvania State College of Medicine, Hersey, PA, USA aut NATIONALLICENCE 700 1- Tjønneland Anne Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Friis Søren Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Christiani David Harvard School of Public Health, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA aut NATIONALLICENCE 700 1- Chun Eun-mi Harvard School of Public Health, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA aut NATIONALLICENCE 700 1- Le Marchand Loic Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, USA aut NATIONALLICENCE 700 1- Rennert Gad Department of Community Medicine and Epidemiology, Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Israel Institute of Technology and Clalit Health Services National Cancer Control Center, Haifa, Israel aut NATIONALLICENCE 700 1- Rennert Hedy Department of Community Medicine and Epidemiology, Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Israel Institute of Technology and Clalit Health Services National Cancer Control Center, Haifa, Israel aut NATIONALLICENCE 700 1- Andrew Angeline Norris Cotton Cancer Center, Department of Community & Family Medicine, Dartmouth Medical School, Lebanon, NH, USA aut NATIONALLICENCE 700 1- Orlow Irene Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut NATIONALLICENCE 700 1- Park Bernard Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut NATIONALLICENCE 700 1- Boffetta Paolo Tisch Cancer Institute and Institute for Translational Epidemiology, Mount Sinai School of Medicine, New York, NY, USA aut NATIONALLICENCE 700 1- Duell Eric Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain aut NATIONALLICENCE 773 0- Cancer Causes & Control Springer Netherlands 22/12(2011-12-01), 1709-1720 0957-5243 22:12<1709 2011 22 10552 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer